Carboplatin for Recurrent Ovarian Cancer
Links shared publicly online about this topic
BMS-345541 + Dasatinib Resensitizes Carboplatin-Resistant, Recurrent Ovarian Cancer Cells « Libby's H*O*P*E*
healthinfoispower.wordpress.com — “BMS-345541 + Dasatinib Resensitizes Carboplatin-Resistant, Recurrent Ovarian Cancer Cells « Libby's H*O*P*E*” View full resource at healthinfoispower.wordpress.com
Most Recently Shared on July 2, 2010 at 2:53 am By:
Paul Cacciatore Patient Advocate
BMS-345541 + Dasatinib Resensitizes Carboplatin-Resistant, Recurrent Ovarian Cancer Cells: http://wp.me/pcE2v-14U
Oncology Article | Carboplatin Ovarian Neoplasms
mdlinx.com — “Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients” View full resource at mdlinx.com
Most Recently Shared on June 2, 2011 at 6:04 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian ... http://bit.ly/jccmI8 #oncology
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - MPR
empr.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at empr.com
Most Recently Shared on June 5, 2011 at 6:53 pm By:
#asco2011 Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in… http://goo.gl/fb/MUWQq
Oncology Article | Camptothecin Ovarian Neoplasms Carboplatin
mdlinx.com — “Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer” View full resource at mdlinx.com
Most Recently Shared on December 7, 2010 at 9:14 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatmen... http://bit.ly/dJ8a4s #oncology
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent Ovarian Cancer - ONA
oncologynurseadvisor.com — “Bevacizumab + carboplatin/gemcitabine followed by bevacizumab until disease progression provided a clinically meaningful benefit in women with platinum-sensitive recurrent ovarian cancer, representing the first Phase 3 trial of an antiangiogenic agent to demonstrate such a benefit, investigators reported during the American Society of Clinical Oncology's 2011 Annual Meeting.” View full resource at oncologynurseadvisor.com
Most Recently Shared on June 5, 2011 at 6:30 pm By:
OncologyNurseAdvisor Oncology, Nursing, Medical Education, and Medical Publisher
Adding Bevacizumab to Carboplatin/Gemcitabine Extends Progression-Free Survival in Recurrent… http://goo.gl/fb/oUkM7
Oncology Article | Carboplatin Ovarian Neoplasms
mdlinx.com — “Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: The Mito-2 Randomized Phase III Trial” View full resource at mdlinx.com
Most Recently Shared on August 18, 2011 at 6:19 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line trea... http://t.co/gQvyhct #oncology
For The Treatment Of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin
medicalnewstoday.com — “Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard o” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2010 at 3:37 pm By:
For The Treatment Of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin De.. http://dld.bz/AcP7
Ob/Gyn Article | Carboplatin Ovarian Neoplasms
mdlinx.com — “Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients” View full resource at mdlinx.com
Most Recently Shared on June 2, 2011 at 7:15 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian can... http://bit.ly/kRnSI9 #OBGYN
Oncology Article | Carboplatin Ovarian Neoplasms Paclitaxel
mdlinx.com — “Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer” View full resource at mdlinx.com
Most Recently Shared on January 31, 2011 at 6:17 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-r... http://bit.ly/eDTbxA #oncology
Oncology Medical News about ovarian cancer
mdlinx.com — “A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer” View full resource at mdlinx.com
Most Recently Shared on January 13, 2010 at 10:11 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Heme/Onc: A phase-I trial of pemetrexed plus carboplatin in recurrent ovarian cancer: Cancer Chemotherapy and Pharmacol http://url4.eu/17I5Z
Oncology Article | Carboplatin Ovarian Neoplasms Paclitaxel
mdlinx.com — “Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery of extended dose dense weekly carboplatin in platinum resistant/ refractory epithelial ovarian cancer” View full resource at mdlinx.com
Most Recently Shared on July 13, 2011 at 7:49 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Sustained platelet-sparing effect of weekly low dose paclitaxel allows effective, tolerable delivery o... http://bit.ly/qLdG64 #oncology
PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-sensitive ovarian cancer
news-medical.net — “Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that although platinum-based treatment will continue to be the standard of care for first- and second-line treatment of platinum-sensitive ovarian cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will replace paclitaxel/carboplatin as the standard second-line treatment for patients who remain platinum sensitive.” View full resource at news-medical.net
Most Recently Shared on December 10, 2010 at 3:43 pm By:
Ovarian Cancer News: PLD/carboplatin to replace paclitaxel/carboplatin as gold-standard treatment for platinum-s... http://bit.ly/gI3hGR
First Recurrent Gene Fusion Identified In Ovarian Cancer
medicalnewstoday.com — “Researchers studying ovarian cancer have discovered that, in a substantial fraction of ovarian tumors, a gene closely related to the estrogen receptor is broken and fused to an adjacent gene by a” View full resource at medicalnewstoday.com
Most Recently Shared on September 22, 2011 at 7:05 am By:
MNT Ovarian Cancer Health News
First Recurrent Gene Fusion Identified In Ovarian Cancer http://mnt.to/3ZMY #ovariancancer
Ovarian cancer vaccine: Can it prevent recurrence? - MayoClinic.com
mayoclinic.com — “Research continues to evaluate the role of an ovarian cancer vaccine to prevent recurrence.” View full resource at mayoclinic.com
Most Recently Shared on March 24, 2012 at 2:20 am By:
Julie Bohlen Health Executive and Active Health Library
Ovarian cancer vaccine: Can it prevent recurrence?: Research continues to evaluate the role of an ovarian cancer... http://t.co/fbwU0zDZ
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer
medicalnewstoday.com — “Ovarian cancer is a major health concern for women and the identification of sensitive biomarkers for early detection and/or monitoring of disease recurrence is of high clinical relevance.” View full resource at medicalnewstoday.com
Most Recently Shared on December 9, 2011 at 9:07 am By:
MNT Ovarian Cancer Health News
Unique Genetic Marker May Improve Detection Of Recurrent Ovarian Cancer http://t.co/7OgdD8rC #ovariancancer
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
Paul Cacciatore
Founder of Libby's H*O*P*E* (*Helping *Ovarian Cancer Survivors *Persevere Through *Education)
-
Sandeep Pulim MD
Over 2K medical journal articles & health news summarized and delivered FREE to 35 specialties daily. Oncology, Rheumatology, Cardiology, Neurology, Psychiatry
-
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
